ALMS at a glance
ALUMIS INC. (ALMS, SEC CIK 1847367) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ALUMIS INC. (ALMS) reported revenue of $24.1 million and a net loss of $243.3 million. Diluted EPS was -$2.86.
- As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding ALUMIS INC. (ALMS) shares worth $245.5 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Goldstein David M on November 2, 2026 of 629 shares at $6.52 per share.
- In the last 90 days, ALMS insiders reported 4 open-market purchases ($10.7M) and 8 open-market sales ($1.0M) on Form 4, a net purchase of $9.7M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $24.1M
- 10-K XBRL
- Insiders · 90 days
- 4 buys · 8 sells
- Net +$9.7M
- 13F holders
- 25 funds
- $245.5M · +0 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $1.9M, down 8% YoY from $2.1M, entirely collaboration revenue
- Net loss $94.9M vs $110.8M YoY, operating loss $99.1M vs $115.3M
- Envu, best-performing program: external R&D costs $42.0M vs $48.9M YoY
- Operating cash use $248.2M for nine months, down from $297.6M; financing provided $367.2M
- Cash, equivalents and marketable securities $431.3M, insufficient for 12 months; NDA submission planned by end of 2026
Risk Factors
- Newly highlighted trade risk: 10% baseline tariff and Section 232 pharmaceutical-ingredient tariffs threaten overseas supply costs and clinical timelines
- Most material clinical update: envu Phase 2b SLE trial failed primary and secondary endpoints in September 2026
- Regulatory risk: EU Pharma Package could reduce data protection and facilitate earlier generic or biosimilar entry after anticipated 2028 implementation
- Financial risk: $431.3 million liquidity insufficient for at least 12 months, with $94.9 million quarterly net loss
- Commercial risk: envu faces approved and late-stage oral competitors across psoriasis and systemic lupus erythematosus indications
AI summary of the ALMS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release covers Alumis fiscal quarter ended September 30, 2026
- Exhibit 99.1 contains the company’s financial results and accompanying management disclosures
Item EX-99.1: Item EX-99.1
- Q3 revenue $1.9M versus $2.1M, while net loss improved to $94.9M from $110.8M
- Cash, equivalents and marketable securities $431.3M, supporting operations and capital needs into Q4 2027
Item EX-99.1: Item EX-99.1
- LUMUS Phase 2b missed primary and secondary endpoints in the overall 408-patient SLE population, weakening near-term lupus prospects
- Prespecified IFNGS-high subgroup showed robust BICLA, CLASI-50, SRI-4, and LLDAS responses, supporting planned Phase 3 regulatory discussions
Item 8.01: Other Events
- September 1, 2026 disclosure covers envudeucitinib Phase 2b LUMUS topline results in systemic lupus erythematosus
- Planned NDA submission in fourth quarter 2026 creates a key regulatory catalyst
Item EX-99.2: Item EX-99.2
- LUMUS Phase 2b missed primary and secondary endpoints overall, materially weakening envudeucitinib’s broad SLE development case
- IFNGS-high subgroup showed stronger efficacy, including BICLA response rates of 40.7% to 52.6% versus 28.6% placebo
Item EX-99.1: Item EX-99.1
- ONWARD3 showed 54% PASI 100 and 75% PASI 90 at 48 weeks, strengthening envudeucitinib’s psoriasis commercial positioning
- FDA NDA submission for moderate-to-severe plaque psoriasis remains targeted for Q4 2026, a key regulatory catalyst
Item 2.02: Results of Operations and Financial Condition
- Press release announces Alumis financial results for quarter ended June 30, 2026
- Exhibit 99.1 contains the underlying results and management commentary for investor review
AI summaries of ALMS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ALMS
Don't miss the next ALMS filing
- Alerts as it files. A push when ALMS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ALMS, by share count.
- Ask anything. An AI agent that reads every ALMS filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Goldstein David M | Sell | Nov 2, 2026 | 629 | $6.52 |
| Drappa Jorn | Sell | Nov 2, 2026 | 593 | $6.52 |
| Hardiman Roy C. | Sell | Nov 2, 2026 | 652 | $6.52 |
| Bradley Mark Christopher | Sell | Nov 2, 2026 | 623 | $6.52 |
| Pangali Sanam | Sell | Nov 2, 2026 | 332 | $6.52 |
| Schroer John R. | Sell | Nov 2, 2026 | 794 | $6.52 |
| AKKARAJU SRINIVAS | Sell | Sep 8, 2026 | 48,066 | $10.55 |
| AKKARAJU SRINIVAS | Buy | Sep 8, 2026 | 273,290 | $10.63 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | - | $24.1M |
| Operating Income | -$158.2M | -$300.8M | -$453.8M |
| Net Income | - | -$294.2M | -$243.3M |
| Op. Margin | - | - | -1886.9% |
| Net Margin | - | - | -1011.7% |
| Balance Sheet | |||
| Total Assets | $89.6M | $341.0M | $411.9M |
| Equity | -$339.3M | $260.1M | $301.3M |
| ROE | - | -113.1% | -80.8% |
| Per Share | |||
| EPS | - | $-10.38 | $-2.86 |
| Cash Flow | |||
| Operating CF | -$130.0M | -$255.1M | -$369.5M |
| CapEx | $4.5M | $1.7M | $653K |
Source: XBRL data in ALUMIS INC. (ALMS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ALMS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 25 | $245.5M |
| Q2 2026 | 25 | $1.01B |
| Q1 2026 | 26 | $580.2M |
| Q4 2025 | 23 | $143.6M |
| Q3 2025 | 22 | $51.7M |
| Q2 2025 | 22 | $34.4M |
| Q1 2025 | 14 | $10.7M |
| Q4 2024 | 8 | $9.3M |
- Millennium Management+2.67M (+405%)
- Morgan Stanley+1.84M (+574%)
- Two Sigma Investments+953.9K (+254%)
- Citigroup+835.3K (+217%)
- State Street Corp+761.0K (+35%)
- T. Rowe Price Group−4.18M (-80%)
- Invesco Ltd−1.05M (-89%)
- D.E. Shaw & Co−657.6K (-68%)
- JPMorgan Chase & Co−564.3K (-58%)
- Principal Financial Group−273.1K (-26%)
- Citadel Advisors LLC+2.39M
- Dimensional Fund Advisors+345.2K
- FMR LLC (Fidelity)−6.77M
- Renaissance Technologies LLC−23.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 165 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ALMS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 8-K | Sep 1, 2026 | - | Analysis | - |
| SC 13D | Aug 17, 2026 | - | - | |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| SC 13G | Aug 6, 2026 | - | - | |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| SC 13G | Jul 27, 2026 | - | - | |
| 4 | Jul 8, 2026 | - | - | - |
| 8-K | Jul 2, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ALMS SEC filings: frequently asked questions
Are ALMS insiders buying or selling?
In the last 90 days, ALUMIS INC. (ALMS) officers, directors and 10% owners reported 4 open-market purchases worth $10.7 million by 1 insider and 8 open-market sales worth $1.0 million by 7 insiders on Form 4, a net purchase of $9.7 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ALMS stock?
As of September 30, 2026, the largest ALUMIS INC. (ALMS) holders among the 13F filers tracked by SignalX were BlackRock ($63.4 million), Vanguard Capital Management LLC ($31.5 million), Millennium Management ($24.6 million), State Street Corp ($21.8 million), Citadel Advisors LLC ($17.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ALMS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ALUMIS INC. (ALMS) reported revenue of $24.1 million and a net loss of $243.3 million. Diluted EPS was -$2.86. The figures come from the XBRL data in the 10-K.
What did ALMS report in its latest 8-K?
ALUMIS INC. (ALMS) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers Alumis fiscal quarter ended September 30, 2026.
What are the latest ALMS SEC filings?
ALUMIS INC. (ALMS) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 4, 2026.
What is ALMS's SEC CIK number?
ALUMIS INC. (ALMS)'s SEC Central Index Key (CIK) is 1847367. EDGAR lists every ALMS filing under that number.
Ask anything about ALMS
The research agent reads ALMS's filings, financials, insider trades and 13F holders, then answers with sources.